Tagged with India,

India The state of Gujarat proudly stands as India’s main pharmaceutical hub, accounting for over 33 percent of the country’s pharmaceutical turnover and 28 percent of its pharmaceutical exports.  Given the tremendous importance of the Indian industry globally, this state therefore emerges as a pharmaceutical hub of global importance.   For…

Opinion This month, Aditya Bhattacharji takes stock of three political issues that are dominating Eurasia Group’s conversations with pharmaceutical firms: global protests, drug pricing, and India’s “Modicare” milestone.    Protests First, the rash of protests unfolding across parts of the Middle East, Asia, and Latin America has piqued firms’ attention—not just…

India Unlike many of his pharma peers, Vivek Sharma worked in operations and finance for two decades before joining the life sciences industry as head of Piramal Pharma Solutions (PPS) in 2011. Already established as one of the world’s leading CDMOs with a presence in North America, Europe, and Asia, Sharma…

China The pharmaceutical industries of China and India, historically focused on their large domestic markets and exports to developed nations, are increasingly forging closer links. With US trade tariffs affecting both countries and regulatory reform underway in China, Indian firms are jumping at the chance to bring their competitively-priced drugs to…

India Aditya Bhattacharji is Healthcare Practice Head at Eurasia Group. In this article, he looks at India’s ambitious healthcare insurance scheme, “Modicare” and delves into some of its critical challenges and associated opportunities for private players.   In theory, India’s states will be able to fine tune Modicare’s implementation to meet their…

India Anay Shukla leads the pharmaceutical, life sciences, med-tech and healthcare practice at Nishith Desai Associates, a leading Indian law firm. In this article, he examines the benefit of the recent policy changes to price controls for innovative drugs in India.  Unlike many other countries, India controls prices of all drugs…

India Dilip Shah, the Secretary-General of the Indian Pharmaceutical Alliance advocates for a stronger and more empowered regulator in India if the country is to build public confidence in its pharma output and drug inspectors.    Improving the image of drug inspectors- will require investments in “infrastructure”. The key elements of this…

India Indian pharma companies provide affordable generic drugs to patients in almost all countries across the globe, hence the reason India has been dubbed ‘ the pharmacy to the world.’ Furthermore, Indian companies are increasingly involved in massive R&D projects in the biologics field and a handful of Indian biosimilars have…

Opinion Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. In this article, he gives his predictions for the political landscape in healthcare for 2019.  The challenges for firms are painfully apparent—there is bipartisan support in the US to lower drug prices, a pervasive sense that traditional advocacy methods are failing in today’s political climate,…

India Although most industry observers expect that Indian pharma exports to the US will pick up again in the coming years, Indian companies have – in the meantime – been rapidly increasing their efforts to develop stronger footprints in strategic emerging market such as Brazil, Russia and some Asian and African…

India In a context where even well-established, multi-billion-dollar domestic companies have received warning letters from the US FDA, quality compliance has clearly become strategically important across all layers of Indian organizations, including formulation and API companies as well as both B2B and B2C players.   My approach is extremely simple: quality…

India One issue grinding the gears of the Indian pharmaceutical industry over recent years has been quality compliance. With a number of pharma manufacturers the recipients of warning letters from the US FDA, increased regulatory scrutiny has caused some consternation, but also progress in quality standards across the board. “I see…